Greenway Greenhouse Cannabis Corp. (GWAY) AI Stock Analysis

• Market Cap: C$27.77M
• Dividend Yield: N/A
• Average Volume (3M): 19.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: 19.66%
• EPS Growth: 84.34%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 132,230,700
• 10 Day Avg. Volume: 16,837
• 30 Day Avg. Volume: 19,312
• PEG Ratio: 0.22
• Price to Book (P/B): 2.75
• Price to Sales (P/S): 3.09
• P/FCF Ratio: 17.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: C$0.18 ▲(5.29% Upside)

The score is primarily held back by weaker financial fundamentals—continued net losses, elevated leverage, and negative TTM operating/free cash flow—despite clear operating improvements. Technicals are mildly constructive in the near term but remain weaker over longer timeframes, while valuation is pressured by negative earnings. A recent positive corporate update provides incremental support but does not outweigh balance-sheet and cash-flow risks.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand and effective market penetration, supporting long-term business expansion and stability.

Gross Margin Improvement

Improved gross margins reflect better cost management and operational efficiency, enhancing profitability potential over the long term.

Strategic Expansion

Entering the UK market through a supply agreement signifies strategic growth and diversification, potentially boosting future revenue streams.

Negative Factors

High Leverage

Elevated leverage can limit financial flexibility and increase risk, potentially impacting the company's ability to invest in growth opportunities.

Negative Cash Flow

Negative cash flow raises concerns about liquidity and the ability to sustain operations without external financing, affecting long-term viability.

Net Losses

Ongoing net losses suggest challenges in achieving profitability, which may hinder investment in growth and affect shareholder returns.

Greenway Greenhouse Cannabis Corp. Business Overview & Revenue Model

Company Description

Greenway Greenhouse Cannabis Corporation engages in the cultivation, processing, and selling of dried cannabis flower and kief. The company was incorporated in 2018 and is based in Kingsville, Canada. Greenway Greenhouse Cannabis Corporation is a subsidiary of Sunrite Greenhouses Ltd.

How the Company Makes Money

Greenway Greenhouse Cannabis Corp. generates revenue primarily through the sale of its cannabis products to various markets, including medical dispensaries and recreational retailers. The company utilizes its state-of-the-art greenhouse facilities to produce cannabis efficiently and sustainably, reducing costs and enhancing product quality. Revenue streams include the sale of dried cannabis flowers, oils, and other derivative products. Key partnerships with distributors and retailers help expand the company's reach and market presence, contributing significantly to its earnings. Additionally, Greenway may engage in strategic collaborations or white-label agreements to further diversify its revenue sources.

Greenway Greenhouse Cannabis Corp. Financial Statement Overview

Summary

Greenway Greenhouse Cannabis Corp. shows significant revenue growth but faces challenges with profitability and cash flow. High leverage and negative earnings margins highlight financial strain, while cash flow issues threaten operational sustainability. Addressing these areas is crucial for financial health improvement.

Income Statement

The company shows a negative gross profit margin and net profit margin in the TTM, indicating difficulty in covering costs. Revenue has grown significantly from the previous year, suggesting potential market expansion. However, the negative EBIT and EBITDA margins reflect operational inefficiencies.

Balance Sheet

The debt-to-equity ratio is high, indicating significant leverage, and the equity ratio shows low equity relative to total assets. ROE is negative due to net losses, highlighting profitability challenges. The balance sheet reflects a risk of financial instability.

Cash Flow

Free cash flow is negative, and both operating and free cash flow to net income ratios are unfavorable, indicating cash flow issues. The growth rate of free cash flow is not positive, suggesting the company struggles to generate cash from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.46M	8.95M	5.23M	5.62M	1.98M	0.00
Gross Profit	3.26M	1.68M	-335.38K	741.99K	844.02K	487.88K
EBITDA	2.34M	972.53K	-2.21M	-632.92K	-1.36M	-727.12K
Net Income	-753.24K	-2.06M	-4.72M	-2.61M	-2.92M	-1.23M
Balance Sheet
Total Assets	32.38M	32.26M	33.09M	35.30M	35.63M	25.11M
Cash, Cash Equivalents and Short-Term Investments	1.77M	3.14M	1.53M	3.64M	7.48M	3.46M
Total Debt	15.68M	15.79M	16.02M	13.96M	16.67M	13.85M
Total Liabilities	22.48M	22.21M	21.17M	20.36M	18.77M	14.85M
Stockholders Equity	9.90M	10.05M	11.92M	14.95M	16.86M	10.26M
Cash Flow
Free Cash Flow	-482.91K	1.61M	-4.96M	-4.38M	-4.10M	-5.95M
Operating Cash Flow	-239.54K	1.81M	-2.05M	2.23M	-1.97M	-592.08K
Investing Cash Flow	-243.37K	-194.37K	-2.92M	428.31K	-2.12M	-5.36M
Financing Cash Flow	0.00	0.00	2.85M	-6.49M	8.12M	7.97M

Greenway Greenhouse Cannabis Corp. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GWAY, the sentiment is Positive. The current price of 0.17 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.17, and below the 200-day MA of 0.20, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 64.47 is Neutral, neither overbought nor oversold. The STOCH value of 73.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:GWAY.

Greenway Greenhouse Cannabis Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DB	64 Neutral	C$60.57M	4.18	21.77%	―	15.11%	―
VEXT	59 Neutral	C$59.44M	-2.37	-21.73%	―	43.56%	-349.41%
ROMJ	55 Neutral	C$33.25M	10.85	7.78%	―	28.55%	―
CXXI	52 Neutral	C$115.53M	-14.81	-9.90%	―	23.29%	33.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GWAY	49 Neutral	C$27.77M	-36.84	-7.43%	―	19.66%	84.34%
AVCN	46 Neutral	C$25.92M	-13.72	-77.67%	―	2.41%	74.61%

Greenway Greenhouse Cannabis Corp. Corporate Events

Greenway Leverages Efficiency Gains and International Expansion to Accelerate Next Growth Phase

In its 2025 year-in-review, Greenway highlighted a year of disciplined execution marked by improved cultivation efficiency, stronger yields and tighter cost controls, which management views as a durable step-change underpinning its profitability strategy. The company advanced its international wholesale program with product now reaching multiple European jurisdictions and Australia, and it signed a strategic supply agreement with 4C Labs to serve the U.K. medical cannabis market, while delivering a 20% increase in annual revenue and a more than 40% rise in average selling price per gram. With additional cultivation capacity already built out that can lift production by over 75% without significant new capital spending, Greenway plans to ramp output in a measured, demand-driven manner, aiming to leverage growing international sales channels to drive higher volumes, revenue growth and operating leverage despite ongoing volatility in the Canadian cannabis sector.

The most recent analyst rating on (TSE:GWAY) stock is a Hold with a C$0.18 price target. To see the full list of analyst forecasts on Greenway Greenhouse Cannabis Corp. stock, see the TSE:GWAY Stock Forecast page.

Greenway Greenhouse Cannabis Corp. Reports Strong Q2 Financials and Strategic Expansion

Greenway Greenhouse Cannabis Corporation reported significant financial improvements in its second quarter of fiscal 2026, with a 60% increase in average net sales price per gram and a 28% reduction in cash cost per gram. The company achieved a gross profit of $827,178, marking a substantial turnaround from a previous gross loss, and improved its gross margin to 40%. The company also entered a supply agreement with 4C LABS in the UK, indicating strategic international expansion. These developments underscore Greenway’s operational efficiency and market positioning, setting a strong foundation for future growth and shareholder value.